Biocept, Inc. (NASDAQ: BIOC) Q3 2022 earnings call dated Nov. 28, 2022 Corporate Participants: Jody Cain -- Investor Relations Samuel D. Riccitelli -- Chairman and interim
Biocept Inc.
-(BIOC)
XNAS:BIOC
Biocept Inc (BIOC) Q2 2021 Earnings Call Transcript
Biocept Inc (NASDAQ:BIOC) Q2 2021 earnings call dated Aug. 16, 2021. Corporate Participants: Bruce Voss -- Investor Relations Michael W. Nall -- President and Chief Executive
Biocept Inc (BIOC) Q4 2020 Earnings Call
Biocept Inc (NASDAQ: BIOC) Q4 2020 earnings call dated Mar. 29, 2021. Corporate Participants: Jody Cain — Investor Relations Michael W. Nall — President and Chief
Biocept Inc (BIOC) Q4 2020 Earnings Call Transcript
Biocept Inc (NASDAQ: BIOC) Q4 2020 earnings call dated Mar. 29, 2021. Corporate Participants: Jody Cain -- Investor Relations Michael W. Nall -- President and Chief
Earnings calendar for the week of March 29
Encouraging data from the labor market and optimism brought on by the stimulus package bolstered stock markets this week. Benchmark indexes Dow
Biocept Inc (BIOC) Q3 2020 Earnings Call
Biocept Inc (NASDAQ: BIOC) Q3 2020 earnings call dated Nov. 12, 2020 Corporate Participants: Bruce Voss -- Investor Relations Michael W. Nall -- President and Chief
Biocept Inc (BIOC) Q3 2020 Earnings Call Transcript
Biocept Inc (NASDAQ: BIOC) Q3 2020 earnings call dated Nov. 12, 2020 Corporate Participants: Bruce Voss -- Investor Relations Michael W. Nall -- President and Chief
Biocept Inc. (BIOC) Q2 2020 Earnings Call Transcript
Biocept Inc. (NASDAQ: BIOC) Q2 2020 earnings call dated Aug. 12, 2020 Corporate Participants: Jody Cain -- Investor Relations Michael W. Nall -- President and Chief
Biocept (BIOC) revenue drops 23% in Q2; loss narrows
Biocept (NASDAQ: BIOC) reported a narrower loss in the second quarter of 2020. The company's revenue declined by 23% year-over-year to $917,000,
Biocept (BIOC) – Is it worth buying?
Investing in microcap stocks are considered to be risky; even higher so in uncertain market environments like the one we are seeing
Biocept Inc. (NASDAQ: BIOC) Q1 2020 Earnings Call Transcript
Biocept Inc. (BIOC) Q1 2020 earnings call dated May 13, 2020 Corporate Participants: Jody Cain -- Investor Relations Michael W. Nall -- President and Chief Executive
Biocept (BIOC) posts wider-than-expected loss in Q4
Biocept, Inc. (NASDAQ: BIOC) reported a narrower loss in the fourth quarter of 2019 driven by higher revenue. The bottom line was
Earnings: Biocept reports net loss for Q2; revenue beats
Biocept (NASDAQ: BIOC), a leading molecular oncology diagnostics company, reported a net loss for the second quarter. Revenues increased sharply and topped
Biocept narrows loss in Q4
Biocept (BIOC) narrowed its loss in the fourth quarter, beating analyst estimates. However, sales failed to impress the street. Shares of the
Earnings preview: What’s on the cards for Biocept in Q4
Biocept (BIOC) is scheduled to report fourth quarter and full year 2018 results on March 28, Thursday, after the regular trading hours.